Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs Inovio Pharmaceuticals Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.81, while Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M). Which is the better fit depends on your goals.

BNDXINO
52-Week High
$49.91$2.87
52-Week Low
$47.57$0.66
Market Cap
$78.55M
Sector
Health
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.82, up 0.06% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. Recent news highlights institutional activity, including Apella Capital reducing its stake and Archer Investment Management increasing holdings. The fund's dividend schedule shows consistent payouts, with the latest dividend of $0.12 scheduled for payment in August 2026.

The outlook for BNDX is cautious due to bearish technical indicators and mixed institutional sentiment. Risks include interest rate volatility and inflation concerns, as highlighted by recent Treasury yield movements. Opportunities lie in its role as a bond ETF providing diversified international fixed income exposure, but investors should weigh macroeconomic factors affecting bond markets.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO